Literature DB >> 11487217

Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.

F Stocchi1, L Vacca, M F De Pandis, L Barbato, M Valente, S Ruggieri.   

Abstract

Fluctuations in motor disability and dyskinesias are the major problem in the long-term treatment of Parkinson's disease (PD). Many authors and ourselves have shown that by giving patients a continuous infusion of levodopa it is possible to control motor fluctuations. Levodopa can be administered continuously only by intravenous, intragastric or intrajejunal delivery. Continuous dopaminergic stimulation can be achieved more easily by infusing dopamine agonists subcutaneously. Apomorphine is a potent water-soluble dopamine receptor agonist that has been shown to successfully control motor fluctuation when subcutaneously infused in complicated parkinsonian patients. We report the clinical data of 30 PD patients having at least five years of treatment with subcutaneous continuous apomorphine infusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487217     DOI: 10.1007/s100720170062

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  17 in total

Review 1.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

2.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation.

Authors:  Angelo Antonini; Ioannis U Isaias; Giorgia Rodolfi; Andrea Landi; Francesca Natuzzi; Chiara Siri; Gianni Pezzoli
Journal:  J Neurol       Date:  2010-10-23       Impact factor: 4.849

Review 3.  Old Drugs, New Delivery Systems in Parkinson's Disease.

Authors:  Harsh V Gupta; Kelly E Lyons; Rajesh Pahwa
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

4.  A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.

Authors:  Hilary L Tyne; Jan Parsons; Ann Sinnott; Susan H Fox; Nicholas A Fletcher; Malcolm J Steiger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

5.  Sensor-based gait analysis of individualized improvement during apomorphine titration in Parkinson's disease.

Authors:  Franz Marxreiter; Heiko Gaßner; Olga Borozdina; Jens Barth; Zacharias Kohl; Johannes C M Schlachetzki; Caroline Thun-Hohenstein; Dieter Volc; Bjoern M Eskofier; Jürgen Winkler; Jochen Klucken
Journal:  J Neurol       Date:  2018-09-08       Impact factor: 4.849

6.  Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.

Authors:  Ángel Sesar; Gustavo Fernández-Pajarín; Begoña Ares; María Teresa Rivas; Alfonso Castro
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

Review 7.  Advanced stages of PD: interventional therapies and related patient-centered care.

Authors:  Rejko Krüger; Rüdiger Hilker; Christian Winkler; Michael Lorrain; Matthias Hahne; Christoph Redecker; Paul Lingor; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2015-07-03       Impact factor: 3.575

Review 8.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.

Authors:  Qing Lv; Baorong Zhang
Journal:  Neurosci Bull       Date:  2013-03-20       Impact factor: 5.203

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.